文献速递眼底病与葡萄膜炎

换用法瑞西单抗治疗难治性新生血管性年龄相关性黄斑变性的临床疗效:系统评价与Meta分析

Clinical Efficacy of Switching to Faricimab in Treatment Resistant Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-analysis.
PubMed 文献 · Am J Ophthalmol · 2025-08-21

该系统评价与Meta分析纳入14项研究共926只眼,评估难治性新生血管性年龄相关性黄斑变性换用法瑞西单抗的疗效。换用后视网膜厚度显著降低46.67微米,视力无变化,采用负荷间隔方案者视网膜厚度降低更明显,注射间隔延长1.56周。

要点

  • 换用法瑞西单抗后视网膜厚度降低46.67微米,采用负荷间隔方案者降低更明显。
  • 最佳矫正视力无变化,基线视力<65个ETDRS字母者视力提高3.16个字母。
  • 获得干性黄斑的比值比为4.35,注射间隔延长1.56周。

核心结论

  • 难治性新生血管性年龄相关性黄斑变性换用法瑞西单抗后视网膜厚度显著改善,但视力无变化。
  • 采用负荷间隔方案者视网膜厚度降低更明显,总体注射间隔延长。
  • 需要进一步的前瞻性研究来优化给药策略并评估长期疗效。

研究设计与样本

  • 系统评价与Meta分析,遵循PRISMA指南,在PROSPERO注册(CRD420251000088)。
  • 检索PubMed、Embase和Scopus(2025年2月3日),纳入报告视网膜厚度、视力、液体状态或注射间隔结局的研究。
  • 纳入标准要求患者既往接受≥3次抗VEGF注射且≥3次法瑞西单抗注射,共纳入14项研究926只眼。
  • 使用ROBINS-I和NIH质量评估工具评估偏倚,使用GRADE评估证据确定性,采用均数差、比值比和随机效应模型进行Meta分析。

主要发现

  • 换用法瑞西单抗后视网膜厚度降低46.67微米(95%CI:35.91-57.42,I²=0%,721只眼)。
  • 采用负荷间隔方案的眼视网膜厚度降低幅度大于未采用者(I²=74.1%,640只眼)。
  • 获得干性黄斑的比值比为4.35(95%CI:2.95-6.42,I²=64%,379只眼)。
  • 基线视力<65个ETDRS字母的眼视力提高3.16个字母(95%CI:0.80-5.52,I²=0%,439只眼)。
  • 注射间隔延长1.56周(95%CI:0.71-2.40,I²=86%,591只眼)。

关键数值与推荐

  • 采用负荷间隔方案者视网膜厚度降低幅度大于未采用者(I²=74.1%,640只眼)。
  • 获得干性黄斑的比值比为4.35(95%CI:2.95-6.42)。
  • 视力、干性黄斑和注射间隔的GRADE证据确定性为极低,视网膜厚度为低。

临床怎么用

  • 原文未据此给出推荐。
  • 作者指出需要进一步的前瞻性研究来优化给药策略并评估长期疗效。

局限性

  • 视力、干性黄斑和注射间隔的GRADE证据确定性为极低,视网膜厚度为低。
  • 注射间隔分析的异质性I²=86%。
  • 需要进一步的前瞻性研究来优化给药策略并评估长期疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC: Faricimab in the treatment of treatment-resistant neovascular age-related macular degeneration (nAMD). CLINICAL RELEVANCE: While many studies on faricimab in treatment-resistant eyes have reported improvements in retinal thickness (RT), the impact on visual acuity (VA) remains inconsistent. Additionally, variability in dosing protocols-with some studies utilizing loading interval for the first 3 injections while others continuing at the prior injection interval-introduces further uncertainty regarding the optimal treatment strategy. Understanding these differences is essential for guiding clinical decision-making and maximizing patient outcomes. METHODS: This systematic review and meta-analysis followed PRISMA guidelines and was registered in PROSPERO (CRD420251000088). A systematic search of PubMed, Embase, and Scopus (February 3, 2025) identified studies evaluating the effects of switching to faricimab in treatment-resistant nAMD. Inclusion criteria required patients to have received ≥3 prior anti-VEGF injections and ≥3 faricimab injections, with reported outcomes on RT, VA, fluid status, or injection intervals. Outcomes were measured following completion of loading dose and at last follow up, ranging from 3 months to 1.5 years. Studies were assessed for bias using ROBINS-I and NIH Quality Assessment tool and assessed for certainty of evidence using GRADE. Meta-analyses were conducted using mean differences, odds ratio, and random-effects models. RESULTS: Fourteen studies (926 eyes) met inclusion criteria. Switching to faricimab significantly reduced RT by 46.67 µm (95% CI: 35.91-57.42, I2 = 0%, 721 eyes). Eyes that followed a loading interval were found to have greater reduction in RT than those that did not (I2 = 74.1%, 640 eyes). The odds of achieving a dry macula increased 4.35-fold (95% CI: 2.95-6.42, I2 = 64%, 379 eyes). Eyes with baseline VA <65 ETDRS letters showed a gain of 3.16 letters (95% CI: 0.80-5.52, I2 = 0%, 439 eyes). Injection intervals were extended by 1.56 weeks (95% CI: 0.71-2.40, I2 = 86%, 591 eyes). Using GRADE, 4 outcomes were graded as either very low (VA, dryness, and treatment interval) or low (RT). CONCLUSION: Switching to faricimab in treatment-resistant nAMD eyes significantly improved RT with no change in VA. This effect was greater with a loading interval protocol. Overall, there was an extension of injection intervals. Further prospective studies are needed to optimize dosing strategies and assess long-term efficacy.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Zhang C, Aboukasm G, Lai DA, et al. Clinical Efficacy of Switching to Faricimab in Treatment Resistant Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-analysis. Am J Ophthalmol. 2025. PMID: 40849032. doi:10.1016/j.ajo.2025.08.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。